<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/16C42590-30C0-4CCE-894F-C4189A4DE800"><gtr:id>16C42590-30C0-4CCE-894F-C4189A4DE800</gtr:id><gtr:name>University of Bordeaux I</gtr:name><gtr:address><gtr:line1>351 Cours de la Liberation</gtr:line1><gtr:postCode>F-33405</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1C702039-D041-41C7-97E6-22CA228D3CC0"><gtr:id>1C702039-D041-41C7-97E6-22CA228D3CC0</gtr:id><gtr:name>International Epidemiologic Databases to Evaluate AIDS (IeDEA)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC9ED2E5-3AE9-4CB4-AD0C-B8953F01D45C"><gtr:id>FC9ED2E5-3AE9-4CB4-AD0C-B8953F01D45C</gtr:id><gtr:name>University of Alabama at Birmingham</gtr:name><gtr:address><gtr:line1>1720 2nd Avenue South</gtr:line1><gtr:line4>Birmingham</gtr:line4><gtr:line5>Alabama 35294-0017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82F274CB-C3AA-445B-9714-3CF56785F38E"><gtr:id>82F274CB-C3AA-445B-9714-3CF56785F38E</gtr:id><gtr:name>Johns Hopkins University</gtr:name><gtr:address><gtr:line1>3400 North Charles Street</gtr:line1><gtr:line4>Baltimore</gtr:line4><gtr:line5>MD 21218</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:department>Social Medicine</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/16C42590-30C0-4CCE-894F-C4189A4DE800"><gtr:id>16C42590-30C0-4CCE-894F-C4189A4DE800</gtr:id><gtr:name>University of Bordeaux I</gtr:name><gtr:address><gtr:line1>351 Cours de la Liberation</gtr:line1><gtr:postCode>F-33405</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1C702039-D041-41C7-97E6-22CA228D3CC0"><gtr:id>1C702039-D041-41C7-97E6-22CA228D3CC0</gtr:id><gtr:name>International Epidemiologic Databases to Evaluate AIDS (IeDEA)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC9ED2E5-3AE9-4CB4-AD0C-B8953F01D45C"><gtr:id>FC9ED2E5-3AE9-4CB4-AD0C-B8953F01D45C</gtr:id><gtr:name>University of Alabama at Birmingham</gtr:name><gtr:address><gtr:line1>1720 2nd Avenue South</gtr:line1><gtr:line4>Birmingham</gtr:line4><gtr:line5>Alabama 35294-0017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82F274CB-C3AA-445B-9714-3CF56785F38E"><gtr:id>82F274CB-C3AA-445B-9714-3CF56785F38E</gtr:id><gtr:name>Johns Hopkins University</gtr:name><gtr:address><gtr:line1>3400 North Charles Street</gtr:line1><gtr:line4>Baltimore</gtr:line4><gtr:line5>MD 21218</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E4D96708-C40B-4B0A-A011-7EE2A61B9945"><gtr:id>E4D96708-C40B-4B0A-A011-7EE2A61B9945</gtr:id><gtr:firstName>Antonella</gtr:firstName><gtr:surname>d Arminio Monforte</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D0041683-19D4-4496-AC2F-7ECAD11307FB"><gtr:id>D0041683-19D4-4496-AC2F-7ECAD11307FB</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:surname>Zangerle</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1677B0C5-59E5-4FE5-8507-E88576587770"><gtr:id>1677B0C5-59E5-4FE5-8507-E88576587770</gtr:id><gtr:firstName>Reinhard</gtr:firstName><gtr:surname>Brodt</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E3D82D6C-A7CB-4D91-9FE2-D1E5B03CFF94"><gtr:id>E3D82D6C-A7CB-4D91-9FE2-D1E5B03CFF94</gtr:id><gtr:firstName>Timothy</gtr:firstName><gtr:surname>Sterling</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3860B699-470A-4E23-8CA5-B8F91856C326"><gtr:id>3860B699-470A-4E23-8CA5-B8F91856C326</gtr:id><gtr:firstName>Miguel</gtr:firstName><gtr:surname>Hernan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C9056EA9-2D86-4BAC-85CC-34D81874F4F4"><gtr:id>C9056EA9-2D86-4BAC-85CC-34D81874F4F4</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:surname>Saag</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BF77ADC2-E3BD-4013-973C-A944991B276B"><gtr:id>BF77ADC2-E3BD-4013-973C-A944991B276B</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Gill</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5D0DD6B8-EEC5-4040-9320-92F6CB776CE8"><gtr:id>5D0DD6B8-EEC5-4040-9320-92F6CB776CE8</gtr:id><gtr:firstName>Gerd</gtr:firstName><gtr:surname>Fatkenheuer</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/75B88BEF-D239-4EBE-B538-0FCDCCE6E80C"><gtr:id>75B88BEF-D239-4EBE-B538-0FCDCCE6E80C</gtr:id><gtr:firstName>Ole</gtr:firstName><gtr:surname>Kirk</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A43E61D5-6E9F-4E5D-AC2A-2718B2E95003"><gtr:id>A43E61D5-6E9F-4E5D-AC2A-2718B2E95003</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Boulle</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3C2E4920-7D46-4F9E-9BE6-4F718C76EA14"><gtr:id>3C2E4920-7D46-4F9E-9BE6-4F718C76EA14</gtr:id><gtr:firstName>Julia</gtr:firstName><gtr:surname>del Amo</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FA3B30E4-7088-448B-A3BA-88DA91611EB6"><gtr:id>FA3B30E4-7088-448B-A3BA-88DA91611EB6</gtr:id><gtr:firstName>Sophie</gtr:firstName><gtr:surname>Abgrall</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2722AFF5-280D-4745-9B50-145872A74A75"><gtr:id>2722AFF5-280D-4745-9B50-145872A74A75</gtr:id><gtr:firstName>Mari</gtr:firstName><gtr:surname>Kitahata</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A9557F77-5D58-4687-B25C-A639AF35E256"><gtr:id>A9557F77-5D58-4687-B25C-A639AF35E256</gtr:id><gtr:firstName>Suzanne</gtr:firstName><gtr:otherNames>Marie</gtr:otherNames><gtr:surname>Ingle</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8FAC1CD1-9011-4485-9962-16E01E16DAF7"><gtr:id>8FAC1CD1-9011-4485-9962-16E01E16DAF7</gtr:id><gtr:firstName>David Hans-Ulrich</gtr:firstName><gtr:surname>Haerry</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/830C1672-D746-4872-B04B-6FF35BC260FF"><gtr:id>830C1672-D746-4872-B04B-6FF35BC260FF</gtr:id><gtr:firstName>Amy</gtr:firstName><gtr:surname>Justice</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3D63A384-98EE-4C63-B7FF-A182D68F700A"><gtr:id>3D63A384-98EE-4C63-B7FF-A182D68F700A</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:surname>Sterne</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/65A15A0B-975F-4A60-BAFC-09378465160B"><gtr:id>65A15A0B-975F-4A60-BAFC-09378465160B</gtr:id><gtr:firstName>Matthias</gtr:firstName><gtr:surname>Egger</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4BB1F803-F380-444A-9841-092737061E15"><gtr:id>4BB1F803-F380-444A-9841-092737061E15</gtr:id><gtr:firstName>Francois</gtr:firstName><gtr:surname>Dabis</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E3440CF5-9B46-4FED-8783-C522D690E640"><gtr:id>E3440CF5-9B46-4FED-8783-C522D690E640</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:surname>Hogg</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/903E6DFF-FE42-41C2-9250-DABD8695FAF0"><gtr:id>903E6DFF-FE42-41C2-9250-DABD8695FAF0</gtr:id><gtr:firstName>Fiona</gtr:firstName><gtr:otherNames>Caroline</gtr:otherNames><gtr:surname>Lampe</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B16E312A-BEFB-4F91-BB58-AD9C631EB3EB"><gtr:id>B16E312A-BEFB-4F91-BB58-AD9C631EB3EB</gtr:id><gtr:firstName>Jodie</gtr:firstName><gtr:surname>Guest</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/62A5B14F-156F-4F9E-980D-75EDE4EA15FD"><gtr:id>62A5B14F-156F-4F9E-980D-75EDE4EA15FD</gtr:id><gtr:firstName>Margaret</gtr:firstName><gtr:surname>May</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2A13B548-CEF1-48DB-8D00-FFB776827D68"><gtr:id>2A13B548-CEF1-48DB-8D00-FFB776827D68</gtr:id><gtr:firstName>Matthew John</gtr:firstName><gtr:surname>Williams</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FB8777EA-55BC-48D2-B979-75F55204ECF0"><gtr:id>FB8777EA-55BC-48D2-B979-75F55204ECF0</gtr:id><gtr:firstName>Frank</gtr:firstName><gtr:surname>de Wolf</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7B2E8F8E-2B1C-4AF0-BB50-7DC552D05763"><gtr:id>7B2E8F8E-2B1C-4AF0-BB50-7DC552D05763</gtr:id><gtr:firstName>Dominique</gtr:firstName><gtr:surname>Costagliola</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5CD86292-EA6C-40A9-9C4A-62FF5F2A720C"><gtr:id>5CD86292-EA6C-40A9-9C4A-62FF5F2A720C</gtr:id><gtr:firstName>Jordi</gtr:firstName><gtr:surname>Casabona</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7B6616CA-0505-47D0-8695-9DE58D6D9E89"><gtr:id>7B6616CA-0505-47D0-8695-9DE58D6D9E89</gtr:id><gtr:firstName>Matthias</gtr:firstName><gtr:surname>Cavassini</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ002380%2F1"><gtr:id>B0217B02-BF55-4058-AA7E-491A1E431877</gtr:id><gtr:title>Prognosis of HIV-positive patients treated with antiretroviral therapy: comparative analyses and treatment strategies</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J002380/1</gtr:grantReference><gtr:abstractText>Highly effective treatments consisting of combinations of different drugs are now available for HIV-positive people and have dramatically reduced the risk of acquired immune deficiency syndromes (AIDS) and death since their introduction in 1996. Increasing numbers of patients have been treated for many years, but outcomes in these people remain unclear, patterns of cause of death have changed, and new predictors of outcomes are emerging. Randomised clinical trials are the best way to examine treatment effects, but most trials in the field rely on outcomes that are measurements from blood tests (rather than AIDS and death, which are of more interest to patients and doctors) and recruit small numbers of patients followed for a short length of time. Trials often exclude sicker patients, and cannot estimate the effectiveness of drugs in important subgroups such as women, those aged &amp;gt;50 years, or ethnic minorities. Many questions relating to treatment strategies cannot be, or have not been, answered in trials. Therefore information about long term outcomes and effects of treatment in patient subgroups must largely rely on large collaborations of HIV cohorts - studies in which groups of HIV positive people are followed over time.
 
This application seeks funding for the ART Cohort Collaboration (ART-CC), an international collaboration that combines data from 19 HIV cohort studies from Europe and North America. It is coordinated by a small team at Bristol University, and administered by a steering committee of representatives from the contributing studies with expertise in HIV medicine, clinical epidemiology and medical statistics, and patient representatives. We will work within European and North American regional collaborations, which will provide considerable value for money because we can take advantage of their data management systems, and also ensure that we have a distinct and unique research agenda. We expect to combine data on at least 100,000 patients. We will work with collaborations in Southern and West Africa in order to compare outcomes among patients treated in these settings, in which resources for treatment and health care are limited, with outcomes among patients treated in Europe and North America. We will update our datasets annually during the period covered by the application.

Our objectives are: (A) Examine the prognosis of patients on treatment for AIDS, deaths from all causes and deaths from specific causes, focusing on prognosis over many years, the role of new factors that predict AIDS and death, and prognosis from some years after starting treatment; (B) Examine differences in prognosis between regions and settings including the roles of gender and ethnic group; (C) Estimate life expectancy, defined as the average number of additional years a person will live, from the time of starting treatment and separately for groups of patients with different characteristics; (D) Conduct collaborative work on prognosis in low income settings, such as sub-Saharan Africa, where the majority of HIV-positive people live. We will use statistical methods that mimic randomised trials using cohort data to: (E) Investigate strategies for regimen modification (switching) in patients in whose blood HIV-1 virus can be detected, and examine risk factors for and prognosis according to the type of regimen change; (F) Estimate the adverse effects of missed doses or interruptions to treatment on clinical outcomes; (G) Examine the best time to start treatment for HIV in patients who also require treatment for other specific infections that occur when the immune system has been damaged and that affect the central nervous system.

Based on our past experience, we expect the results of this research to be of direct relevance to the care of HIV-positive people and to be incorporated into treatment guidelines. We will provide online risk and life expectancy calculators, as well as summaries for patients, on the study web site.</gtr:abstractText><gtr:technicalSummary>Antiretroviral therapy (ART) dramatically reduces rates of AIDS and death in HIV-positive people in Europe, North America and low-income settings, particularly those who start early and attain viral suppression. However mortality rates still exceed those in the general population, and there are increasing numbers of older patients and those treated for many years. Predictors of prognosis are changing to include factors beyond conventional markers of HIV disease progression: long term outcomes remain unclear. This application seeks funding for a collaboration of 19 European and North American HIV cohort studies. Working within regional collaborations, we plan to combine data on &amp;gt;100000 treated patients and compare outcomes with those in Southern and West Africa. Objectives are: A) Examine prognosis for AIDS and deaths from all and specific causes among patients on ART, focusing on non-HIV biomarkers, additional CD4 measures, co-infections, new measures of and interactions with HIV virus burden, and HIV-1 subtype; B) Investigate heterogeneity in outcomes between regions and settings; C) Estimate life expectancy overall and in subgroups; D) Conduct collaborative work on prognosis in low-income settings (comparison of mortality in S. Africa, Europe and N. America allowing for incomplete death ascertainment, and prognosis for HIV-2 in W. Africa). We will use causal inference methods to examine optimal treatment strategies including E) strategies for regimen modification (switching) in patients with virological failure of first ART regimen; F) effect of non-adherence to ART on treatment failure and progression to AIDS and death; G) optimal timing of ART in patients presenting with specific CNS AIDS-defining opportunistic infections such as cryptococcal meningitis and toxoplasmic encephalitis. We expect our research results to be of direct relevance to the care of HIV-positive people and to be published in high impact journals and incorporated in treatment guidelines.</gtr:technicalSummary><gtr:potentialImpactText>Our research programme aims to provide information that will be directly useful to patients and health professionals making decisions about antiretroviral therapy (ART). An improved understanding of factors predicting prognosis among treated patients will help doctors and other health professionals improve and optimise care for high-risk patients and guide patients on ways to improve their prognosis. Our previous work has directly influenced, and been highly cited in, national and international treatment guidelines on treatment of HIV-positive people, and the objectives of our current application address questions of direct relevance to formulation of future guidelines. We will respond to requests for additional analyses from those writing guidelines (for example, the World Health Organisation (WHO)).

Prognostic models are important in enabling policy-makers and those planning health services to predict levels of care that will be needed by an increasing and aging population of treated HIV-positive people. Defining the burden of morbidity and mortality associated with HIV in the era of combination ART will help future planning of both health service provision and social welfare. ART is an expensive treatment that has to be taken for life, but costs may reduce as some drugs come off-patent in the coming years. Our work will assist in studies of the optimum choice of initial ART regimen, balancing effects on rates of AIDS and death, regimen durability, and costs.

Our work on heterogeneity will provide insights into the influence of health systems on outcomes, and an improved understanding of differences between patient groups (for example, according to sex or ethnicity) will enable targeting of groups in which outcomes are sub-optimal, for example because of imperfect adherence, presence of modifiable risk factors or a need for improved treatment of comorbidities.

Estimates of life-expectancy will enable health professionals to answer one of the most common questions asked by patients considering starting ART, or changing or interrupting their regimen - &amp;quot;How long have I got to live?&amp;quot;. We will work with the insurance industry to promote life insurance for treated HIV-positive people, by providing estimates in the form required for actuarial calculations.

Comparisons between outcomes of ART in high and low income settings are key to identifying problems of delivering ART in low income settings (for example, very high early mortality), as well as demonstrating that excellent outcomes can be achieved with much more limited resources than are available in Europe or North America.

Randomised clinical trials (RCTs) underpin decisions about optimal treatments and treatment strategies, but many questions about ART cannot be, or have not yet been, addressed in RCTs. The best available alternative is to conduct analyses of cohort studies using methods that mimic RCTs and can hence provide causal inferences, based on strong but clearly defined assumptions. We will use these methods to answer questions about effects of ART regimen modification (switching), non-adherence to ART, and the optimal timing of ART. Results of this work will again be directly useful to health professionals and patients making treatment decisions.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>589409</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bordeaux</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>WADA</gtr:description><gtr:id>06D3E69D-6BD8-4994-83A2-1D118016BBDF</gtr:id><gtr:impact>paper in press</gtr:impact><gtr:outcomeId>56aa23575d8c68.06769298-1</gtr:outcomeId><gtr:partnerContribution>Data, medical expertise, statistical analyses.</gtr:partnerContribution><gtr:piContribution>Collaborative analysis of data on HIV-2 infected persons in West Africa</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Alabama at Birmingham</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>CNICS</gtr:description><gtr:id>D9D00A5D-528C-4167-99E0-1BAAFA250966</gtr:id><gtr:impact>dataset</gtr:impact><gtr:outcomeId>PrAveMjRkya-1</gtr:outcomeId><gtr:partnerContribution>Data contributed to opportunistic infection modelling.</gtr:partnerContribution><gtr:piContribution>Statistical modelling.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health and Medical Research (INSERM)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>INSERN (1053) (Universit? Bordeaux Segalen)</gtr:department><gtr:description>COHERE</gtr:description><gtr:id>09F4C728-0DCF-4CF9-9015-2E9F44E7F069</gtr:id><gtr:impact>Published papers by ART-CC used data managed by COHERE.</gtr:impact><gtr:outcomeId>ZccMrwcLaw1-1</gtr:outcomeId><gtr:partnerContribution>Management of database and scientific advice.</gtr:partnerContribution><gtr:piContribution>Scientific advice.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International Epidemiologic Databases to Evaluate AIDS (IeDEA)</gtr:collaboratingOrganisation><gtr:country>Central African Republic</gtr:country><gtr:department>IeDEA West Africa Region</gtr:department><gtr:description>IeDEA West Africa</gtr:description><gtr:id>4E6B61CC-41FF-4770-A226-5348754E3285</gtr:id><gtr:impact>Paper in Press</gtr:impact><gtr:outcomeId>eYEDJiiiau9-1</gtr:outcomeId><gtr:partnerContribution>Prognostic modelling methodology for HIV-1 and HIV-2 modelling</gtr:partnerContribution><gtr:piContribution>Prognostic modelling methodology for HIV-1 and HIV-2 modelling</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Population Health Sciences</gtr:department><gtr:description>UKCHIC</gtr:description><gtr:id>3ACAAA46-ED34-4655-9A02-E93A5525AF52</gtr:id><gtr:impact>2 life expectancy papers
subtypes paper in press with AIDS</gtr:impact><gtr:outcomeId>56aa36cca08e98.36373926-1</gtr:outcomeId><gtr:partnerContribution>Supplied data, expertise on HIV.</gtr:partnerContribution><gtr:piContribution>Collaboratively worked on 2 studies on life expectancy of people treated for HIV infection. Analysed data, wrote papers, and presented at conferences. Collaborated on subtypes analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johns Hopkins University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Johns Hopkins Bloomberg School of Public Health</gtr:department><gtr:description>NA-ACCORD</gtr:description><gtr:id>F4F9FA3D-4BDF-444A-9B1C-A666258F9CC8</gtr:id><gtr:impact>dataset</gtr:impact><gtr:outcomeId>HuZrmPBTuRx-1</gtr:outcomeId><gtr:partnerContribution>Data for project on opportunistic infections</gtr:partnerContribution><gtr:piContribution>Statistical modelling</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>IEDEA South Africa</gtr:description><gtr:id>A62D9284-0766-4345-83F8-E7C62792C69E</gtr:id><gtr:impact>IEDEA South Africa is a collaboration of HIV clinic cohorts in Sub Saharan Africa, funded by the US National Institutes of Health, with which we collaborate closely. The following publications have resulted from this collaboration: 18981768, 18670668, 18373510, 18240981, 19142294</gtr:impact><gtr:outcomeId>1473A51093A-1</gtr:outcomeId><gtr:partnerContribution>Comparative analyses of data from low and high income settings</gtr:partnerContribution><gtr:piContribution>The IEDEA collaboration is a global network of HIV cohort collaborations funded by the US National Institutes of Health. Sterne and May are collaborators with the IEDEA Southern Africa collaboration (Principal Investigator Matthias Egger)</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Harvard T.H. Chan School of Public Health</gtr:department><gtr:description>HIV-CAUSAL</gtr:description><gtr:id>EED15E24-04D1-4EB4-B862-E19FB038EDBB</gtr:id><gtr:impact>Paper of effect of ART.</gtr:impact><gtr:outcomeId>D6PjX1QegRE-1</gtr:outcomeId><gtr:partnerContribution>Data and statistical modelling.</gtr:partnerContribution><gtr:piContribution>Statistical modelling and data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Copenhagen</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:department>Copenhagen HIV Programme (CHIP)</gtr:department><gtr:description>COHERE</gtr:description><gtr:id>75F2F7AE-5A20-444D-8214-D5F85146C334</gtr:id><gtr:impact>Published papers by ART-CC used data managed by COHERE.</gtr:impact><gtr:outcomeId>ZccMrwcLaw1-2</gtr:outcomeId><gtr:partnerContribution>Management of database and scientific advice.</gtr:partnerContribution><gtr:piContribution>Scientific advice.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Conference on Retroviruses and Opportunistic Infections</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8910E53C-BB4B-4AAC-A283-C4409BCDD1EC</gtr:id><gtr:impact>Attended the Conference on Retroviruses and Opportunistic Infections every year to present work, support team members and lead the ART-CC collaboration in its work on HIV-1 patients. This is a major, international conference with an audience of around 4,000 researchers in the field of opportunistic infections and retroviruses.</gtr:impact><gtr:outcomeId>56bdb8f74ba456.51083378</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.croiconference.org/</gtr:url><gtr:year>Pre-2006,2006,2007,2008,</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centenary celebrations</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>C1F5A392-24E9-4032-A8D5-CD713FC2E2F3</gtr:id><gtr:impact>Gave 2 round table presentations and discussions as part of an evening of showcasing MRC research.

Raised public awareness of HIV issues.</gtr:impact><gtr:outcomeId>sqGpcXLcmiL</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6F9C0FE0-04A5-4B93-AF7F-0643B64FD9AD</gtr:id><gtr:title>Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0bfb861f5cf1f76dc091b8fcd6f34e9"><gtr:id>e0bfb861f5cf1f76dc091b8fcd6f34e9</gtr:id><gtr:otherNames>Antiretroviral Therapy Cohort Collaboration (ART-CC)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5675dfcba3dc8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B7ED0EC-6E2E-4AAB-8160-3480D74AAA91</gtr:id><gtr:title>Joint longitudinal hurdle and time-to-event models: an application related to viral load and duration of the first treatment regimen in patients with HIV initiating therapy.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f2d709a203778a84efba3225b48dc8e"><gtr:id>5f2d709a203778a84efba3225b48dc8e</gtr:id><gtr:otherNames>Brilleman SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>585d6da0b51ec4.55318781</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78642A48-4A1A-4AB5-8C8B-0B1F99D3B845</gtr:id><gtr:title>Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals.</gtr:title><gtr:parentPublicationTitle>Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abe0206decb5898e085084e699c825fa"><gtr:id>abe0206decb5898e085084e699c825fa</gtr:id><gtr:otherNames>Cain LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0025-7974</gtr:issn><gtr:outcomeId>582f14c14d8f02.84808949</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B4C9031-F65A-4BAF-996E-DDFA1B8BE093</gtr:id><gtr:title>Mathematical modelling of HIV prevention intervention.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7a7c4dd8930be4515c3adc5f9579ee3"><gtr:id>f7a7c4dd8930be4515c3adc5f9579ee3</gtr:id><gtr:otherNames>Thi?baut R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56aa3c34617f37.80486278</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A7ADA59-87EE-4150-8CD7-FCFF4C05530B</gtr:id><gtr:title>Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC).</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/991cf92a3d257a570ad0cfac152b2d53"><gtr:id>991cf92a3d257a570ad0cfac152b2d53</gtr:id><gtr:otherNames>May MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn><gtr:outcomeId>pm_14014_24_23599235</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A42961B6-C867-4FB3-A74A-31A37B0C98D7</gtr:id><gtr:title>Immunologic response in treatment-na&amp;iuml;ve HIV-2-infected patients: the IeDEA West Africa cohort.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b149344ba5fe078eb0f5bf9bd1cd8f95"><gtr:id>b149344ba5fe078eb0f5bf9bd1cd8f95</gtr:id><gtr:otherNames>Balestre E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>56c3414aaa57a6.06433657</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83CBFDA5-6440-43D6-8354-FDC140AE979C</gtr:id><gtr:title>Impact of Low-Level Viremia on Clinical and Virological Outcomes in Treated HIV Infected Patients</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee8658446662f07c83bd6b253fe4ad0a"><gtr:id>ee8658446662f07c83bd6b253fe4ad0a</gtr:id><gtr:otherNames>Vandehende, M.A.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56c1f881556619.53568310</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38E43EF7-4206-4059-A437-2EEDC78C7686</gtr:id><gtr:title>Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/991cf92a3d257a570ad0cfac152b2d53"><gtr:id>991cf92a3d257a570ad0cfac152b2d53</gtr:id><gtr:otherNames>May MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn><gtr:outcomeId>56794912922757.95790959</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2041278E-1A73-40E7-BC6A-A4E929413216</gtr:id><gtr:title>Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study</gtr:title><gtr:parentPublicationTitle>The Lancet HIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e11278ba61455a36f2f10f2e4197101"><gtr:id>2e11278ba61455a36f2f10f2e4197101</gtr:id><gtr:otherNames>Caniglia E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>594ba829039ac8.37969986</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A6E3CC2-5117-4B3C-9CB4-343D90CDB7E7</gtr:id><gtr:title>Sex differences in overall and cause-specific mortality among HIV-infected adults on antiretroviral therapy in Europe, Canada and the US.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0bfb861f5cf1f76dc091b8fcd6f34e9"><gtr:id>e0bfb861f5cf1f76dc091b8fcd6f34e9</gtr:id><gtr:otherNames>Antiretroviral Therapy Cohort Collaboration (ART-CC)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>5675da3fdbc98</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A55DB1C8-3F81-469A-991C-37B6D22B04FE</gtr:id><gtr:title>Insurability of HIV-positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2b6ce2bc7281ddef0c5ea2af71f7e7e"><gtr:id>e2b6ce2bc7281ddef0c5ea2af71f7e7e</gtr:id><gtr:otherNames>Kaulich-Bartz J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_12961_21_23449349</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40921634-49B6-4438-AF44-D7602B540FCE</gtr:id><gtr:title>Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7cb99db5b22ef00de17a26a8de1511e9"><gtr:id>7cb99db5b22ef00de17a26a8de1511e9</gtr:id><gtr:otherNames>Ch?ne G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn><gtr:outcomeId>586e6c7def0782.71812237</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>619359A6-8F41-40BE-9110-E816694B74B7</gtr:id><gtr:title>Impact of Opioid Substitution Therapy on Antiretroviral Therapy Outcomes: A Systematic Review and Meta-Analysis.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03b5c47b336c255b34867223325add41"><gtr:id>03b5c47b336c255b34867223325add41</gtr:id><gtr:otherNames>Low AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>5a3bc4b9307659.69239503</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5ADF934F-C38A-4239-BC27-B0AF7197CA9E</gtr:id><gtr:title>Effect of hepatitis C treatment on CD4+ T-cell counts and the risk of death in HIV-HCV-coinfected patients: the COHERE collaboration.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a06e55f228cd5a3efbb188f76736071"><gtr:id>1a06e55f228cd5a3efbb188f76736071</gtr:id><gtr:otherNames>HCV working group of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>5679444ea20916.46178926</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A849503B-B592-4CEA-A76E-AF977C99A751</gtr:id><gtr:title>Impact of smoking on life expectancy among HIV-infected individuals: The ART Cohort Collaboration</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81f43d99bb0363565776dcbdab9bebcb"><gtr:id>81f43d99bb0363565776dcbdab9bebcb</gtr:id><gtr:otherNames>Helleberg, M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56c1fa0ed09ab7.15817471</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>766E324E-D6A2-49EF-9A6B-07B97E5C0742</gtr:id><gtr:title>Causal inference for dynamic treatment regimens: how analyses of observational data changed international guidelines on when to start antiretroviral therapy,</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7ddcd487f09db4186cd29b6c9a89a65"><gtr:id>a7ddcd487f09db4186cd29b6c9a89a65</gtr:id><gtr:otherNames>STERNE, J.A.C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>56c3379b888c24.23355411</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7459D3AC-9F8A-496D-B92B-6D779CC7EB08</gtr:id><gtr:title>Fitting fixed- and random-effects meta-analysis models using structural equation modeling with the sem and gsem commands</gtr:title><gtr:parentPublicationTitle>STATA JOURNAL</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77a1362d27b7b5182b13c1d3bf4a2cea"><gtr:id>77a1362d27b7b5182b13c1d3bf4a2cea</gtr:id><gtr:otherNames>Palmer Tom M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1536-867X</gtr:issn><gtr:outcomeId>56aa3225d06fa8.00785728</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18A60140-9FF0-4B4C-81FE-19DC44EA0C58</gtr:id><gtr:title>Mind the gap: difference between Framingham heart age and real age increases with age in HIV-positive individuals-a clinical cohort study.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63e72f00cc5affe9e2c251490f4f2e05"><gtr:id>63e72f00cc5affe9e2c251490f4f2e05</gtr:id><gtr:otherNames>Davies TL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>5450c830cd6d99.18244291</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D0AC7C9-3F8A-4ECA-92A3-BECCAA0AF076</gtr:id><gtr:title>Prognosis of children with HIV-1 infection starting antiretroviral therapy in Southern Africa: a collaborative analysis of treatment programs.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e6c44a04cc61e1f1d3370cdb8f2b7556"><gtr:id>e6c44a04cc61e1f1d3370cdb8f2b7556</gtr:id><gtr:otherNames>Davies MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>pm_540e191e1914b78f7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13F628B1-0904-4893-9CBA-3F6FB6A9495E</gtr:id><gtr:title>Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/628876c9fd50086d424d3939e9b327dc"><gtr:id>628876c9fd50086d424d3939e9b327dc</gtr:id><gtr:otherNames>Ingle SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_540e155e155a5be89</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC395902-4EDB-4387-8530-793797DC3C10</gtr:id><gtr:title>Predicting virological decay in patients starting combination antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d0ae6e7a98bbd0f130691f9c6ce1e21"><gtr:id>5d0ae6e7a98bbd0f130691f9c6ce1e21</gtr:id><gtr:otherNames>UK Collaborative HIV Cohort (UK CHIC) Writing Committee</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5846befceba843.97433967</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21FCC1DA-003A-4FB8-9E24-0F5B3E80DF3A</gtr:id><gtr:title>Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.</gtr:title><gtr:parentPublicationTitle>The lancet. HIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3bb7550f609baa2a9b35e3e68f3c7c7"><gtr:id>d3bb7550f609baa2a9b35e3e68f3c7c7</gtr:id><gtr:otherNames>Lodi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2352-3018</gtr:issn><gtr:outcomeId>56793f0e22a8a0.14939282</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B73E3AD-36D2-4052-BDDB-EB9F64A70E18</gtr:id><gtr:title>Impact of ART on Mortality in Cryptococcal Meningitis Patients: High-Income Settings</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/530b879654d5f0bf2bc6e1068a065713"><gtr:id>530b879654d5f0bf2bc6e1068a065713</gtr:id><gtr:otherNames>Ingle, S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56bdbb53598413.28159382</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB2025D6-A3D6-45A4-835A-EA9E3509BD33</gtr:id><gtr:title>The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6f0453a121999165934fdb45d5f7914"><gtr:id>f6f0453a121999165934fdb45d5f7914</gtr:id><gtr:otherNames>Murray M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>DB3isVcHDXH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A017E961-1A74-42C7-B16B-B7EB03AAE21B</gtr:id><gtr:title>Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015.</gtr:title><gtr:parentPublicationTitle>The lancet. HIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e0b39cb771158d3b6d713140f988bda"><gtr:id>0e0b39cb771158d3b6d713140f988bda</gtr:id><gtr:otherNames>GBD 2015 HIV Collaborators</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2352-3018</gtr:issn><gtr:outcomeId>585d4c9a9157e9.83504517</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67466B7C-BCAA-40CA-9572-3EC96CAD65B2</gtr:id><gtr:title>Causal inference for dynamic treatment regimens: how analyses of observational data changed international guidelines on when to start antiretroviral therapy.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/581f630b37a454fc3bd2fbf6859753a4"><gtr:id>581f630b37a454fc3bd2fbf6859753a4</gtr:id><gtr:otherNames>STERNE J.A.C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>56c3370982e5e1.71867082</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01A30D77-FB51-4508-A41A-A71A50656587</gtr:id><gtr:title>Life expectancy living with HIV: recent estimates and future implications.</gtr:title><gtr:parentPublicationTitle>Current opinion in infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76e8cdc063e1304506f5c448f8f89b8c"><gtr:id>76e8cdc063e1304506f5c448f8f89b8c</gtr:id><gtr:otherNames>Nakagawa F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0951-7375</gtr:issn><gtr:outcomeId>pm_12961_21_23221765</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D86032C-29C5-4718-AA6A-E257AAEE0AA1</gtr:id><gtr:title>Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be7c1fedbdc98e219e9a23a167836270"><gtr:id>be7c1fedbdc98e219e9a23a167836270</gtr:id><gtr:otherNames>Glass TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56793f5488db77.47364866</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38C41381-0DF2-4978-AFB5-D4795C392CB8</gtr:id><gtr:title>Influence of geographical origin and ethnicity on mortality in patients on antiretroviral therapy in Canada, Europe, and the United States.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0bfb861f5cf1f76dc091b8fcd6f34e9"><gtr:id>e0bfb861f5cf1f76dc091b8fcd6f34e9</gtr:id><gtr:otherNames>Antiretroviral Therapy Cohort Collaboration (ART-CC)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>5679446c256f83.68313569</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC1B4662-E5B4-465D-B96B-2B19B615C180</gtr:id><gtr:title>An internationally generalizable risk index for mortality after one year of antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40dc33df2adbb2397e9dbe8fbc9303ae"><gtr:id>40dc33df2adbb2397e9dbe8fbc9303ae</gtr:id><gtr:otherNames>Tate JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_14014_24_23095314</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17B9257C-BD4A-48ED-8D70-F76B900CC56E</gtr:id><gtr:title>Associations of Self-reported and Prescription-based Adherence with Viral Suppression in Five HIV Cohort Studies</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab32148f39a54b1db8563e8d6d61fb13"><gtr:id>ab32148f39a54b1db8563e8d6d61fb13</gtr:id><gtr:otherNames>Ingle, S.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>56c1faa517c556.27625106</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61428288-82B6-47E6-B3A5-C667AB0DCBB9</gtr:id><gtr:title>Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/991cf92a3d257a570ad0cfac152b2d53"><gtr:id>991cf92a3d257a570ad0cfac152b2d53</gtr:id><gtr:otherNames>May MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>5675e1f2f2821</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCF11D51-B8DA-4057-8DAC-0957704A9234</gtr:id><gtr:title>Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70f75d64af3a046753f0fbd3b32aab3b"><gtr:id>70f75d64af3a046753f0fbd3b32aab3b</gtr:id><gtr:otherNames>Trickey A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>582f15f192f371.27318995</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3C1F449-5A43-4E08-A8DD-170ACCE81C49</gtr:id><gtr:title>Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/991cf92a3d257a570ad0cfac152b2d53"><gtr:id>991cf92a3d257a570ad0cfac152b2d53</gtr:id><gtr:otherNames>May MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_540e155e1559a8dbf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2C03D20-B537-43E9-8D1E-6D627CEFC300</gtr:id><gtr:title>Association of CD4:CD8 With Cause-Specific Mortality in Patients on Long-Term ART</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10b2c737f18e579ac200ee1ca5f57582"><gtr:id>10b2c737f18e579ac200ee1ca5f57582</gtr:id><gtr:otherNames>May, M.T.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56c1f6c8b9e496.80544879</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B22AC241-3C68-4DD0-934F-5F05BD5314BD</gtr:id><gtr:title>Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/197ad22db7b87dd4874b260f40c9d828"><gtr:id>197ad22db7b87dd4874b260f40c9d828</gtr:id><gtr:otherNames>Abgrall S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5675d863442a2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E13C06BF-3ABB-4426-B890-9711DA860034</gtr:id><gtr:title>CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC).</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70f75d64af3a046753f0fbd3b32aab3b"><gtr:id>70f75d64af3a046753f0fbd3b32aab3b</gtr:id><gtr:otherNames>Trickey A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>5a70f16173d195.37480672</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D8C1E4B-80FA-469F-82DB-884BEE29BDB3</gtr:id><gtr:title>Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ca1a8c279e48d4c8dcd5f4c2e967753"><gtr:id>1ca1a8c279e48d4c8dcd5f4c2e967753</gtr:id><gtr:otherNames>Pettit AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>5a679508413b16.58362279</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF3E2632-B6D3-45AA-B0EF-D32726C76705</gtr:id><gtr:title>Immunodeficiency at the start of ART: Global view</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/82a9a381de2ab654051026a00cf70fe8"><gtr:id>82a9a381de2ab654051026a00cf70fe8</gtr:id><gtr:otherNames>Mugglin, C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>56c1fd38d05da9.74078069</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF085CF8-B2B9-47AA-9046-D17DDCE5FAA9</gtr:id><gtr:title>Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0bfb861f5cf1f76dc091b8fcd6f34e9"><gtr:id>e0bfb861f5cf1f76dc091b8fcd6f34e9</gtr:id><gtr:otherNames>Antiretroviral Therapy Cohort Collaboration (ART-CC)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>582f17443dc922.90599154</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0390AA0-E30F-489C-B6C1-5D3252157F0A</gtr:id><gtr:title>Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bcdb6bf35dccf2dd1717561b55531586"><gtr:id>bcdb6bf35dccf2dd1717561b55531586</gtr:id><gtr:otherNames>Fox MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>pm_12961_21_22433846</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E55384EE-B4F7-433B-8BB4-D53FDC400C40</gtr:id><gtr:title>Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0bfb861f5cf1f76dc091b8fcd6f34e9"><gtr:id>e0bfb861f5cf1f76dc091b8fcd6f34e9</gtr:id><gtr:otherNames>Antiretroviral Therapy Cohort Collaboration (ART-CC)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5679449552ea83.55321923</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8FBF2AB-E7E4-4975-985A-F3B10A9A37BF</gtr:id><gtr:title>When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91e9e79ddc1ff12466df8f0af4fb3c40"><gtr:id>91e9e79ddc1ff12466df8f0af4fb3c40</gtr:id><gtr:otherNames>Caniglia EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>582f1771363b58.82671719</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F9D7E44-BD6B-4B48-916D-9FF41D97A4C3</gtr:id><gtr:title>Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies</gtr:title><gtr:parentPublicationTitle>The Lancet HIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70f75d64af3a046753f0fbd3b32aab3b"><gtr:id>70f75d64af3a046753f0fbd3b32aab3b</gtr:id><gtr:otherNames>Trickey A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>594ba6f5116186.82560351</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53A2F522-BD12-4C89-925B-C130C7F2910C</gtr:id><gtr:title>Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/991cf92a3d257a570ad0cfac152b2d53"><gtr:id>991cf92a3d257a570ad0cfac152b2d53</gtr:id><gtr:otherNames>May MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>5847d8ffb1ef42.17617139</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57C2FC0B-F5E0-44DD-9159-5C026CA1DED1</gtr:id><gtr:title>Survival in individuals living with HIV.</gtr:title><gtr:parentPublicationTitle>Current opinion in HIV and AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d5af412447d4cb7cd648c22233832e5"><gtr:id>0d5af412447d4cb7cd648c22233832e5</gtr:id><gtr:otherNames>Costagliola D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1746-630X</gtr:issn><gtr:outcomeId>585d4c9bcc2219.42098047</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>458E81BE-999D-4EA0-9270-682E4E055196</gtr:id><gtr:title>Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ded355ac2c46668fd5d3aaae309792d2"><gtr:id>ded355ac2c46668fd5d3aaae309792d2</gtr:id><gtr:otherNames>del Amo J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>567945c482f540.23794779</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44FBDA5D-2127-492C-A8DF-236099523E87</gtr:id><gtr:title>Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42d152938bf229c1e5f6d40857170522"><gtr:id>42d152938bf229c1e5f6d40857170522</gtr:id><gtr:otherNames>IeDEA and ART Cohort Collaborations</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>pm_540e155e1558ef38e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6F1B653-8CB6-4633-A2E2-D054878886C1</gtr:id><gtr:title>Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abe0206decb5898e085084e699c825fa"><gtr:id>abe0206decb5898e085084e699c825fa</gtr:id><gtr:otherNames>Cain LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn><gtr:outcomeId>56aa39884f2027.04530712</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8B369FF-56CE-4921-B7B3-14913EE51CCA</gtr:id><gtr:title>Cumulative Viral Load Predicts All-Cause and AIDS-Related Mortality After Initiation of ART</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/502d96f13dfd885e174dcde339f7aae2"><gtr:id>502d96f13dfd885e174dcde339f7aae2</gtr:id><gtr:otherNames>Mugavero, M.J.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56c1f80aece274.25410464</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA601D72-0045-4A3B-84CE-9D136A77B9EE</gtr:id><gtr:title>Long-term mortality in HIV-positive individuals virally suppressed for &amp;gt;3 years with incomplete CD4 recovery.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5754a6c189699f93dc0d4ebf6bd186d"><gtr:id>a5754a6c189699f93dc0d4ebf6bd186d</gtr:id><gtr:otherNames>Engsig FN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>5450c0c19bdfb2.05444858</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C4D370D-6B2E-4FEA-B512-FB3EE2C33AB7</gtr:id><gtr:title>The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abe0206decb5898e085084e699c825fa"><gtr:id>abe0206decb5898e085084e699c825fa</gtr:id><gtr:otherNames>Cain LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>567946bcd2ce30.97982435</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A90E3126-10BE-4466-9A8D-9A2CB360932A</gtr:id><gtr:title>Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a0b2053d0226a3b151c239c08c11329"><gtr:id>1a0b2053d0226a3b151c239c08c11329</gtr:id><gtr:otherNames>Helleberg M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>doi_55faa2aa243aa69f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6711C37-42A0-42FA-A894-3EF1DF6882BA</gtr:id><gtr:title>Methodological and statistical issues related to analysis of survival - Authors' reply</gtr:title><gtr:parentPublicationTitle>The Lancet HIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70f75d64af3a046753f0fbd3b32aab3b"><gtr:id>70f75d64af3a046753f0fbd3b32aab3b</gtr:id><gtr:otherNames>Trickey A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a3bc4b9678990.36208847</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61BE4700-43BE-4A5A-9848-BB8B35BD2CEB</gtr:id><gtr:title>Collaborative Analysis of International Epidemiologic Databases to Evaluate AIDS in Southern Africa and ART Cohort Collaboration Cohorts</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a97bb6f5984e9076ea21c5cccae13d3a"><gtr:id>a97bb6f5984e9076ea21c5cccae13d3a</gtr:id><gtr:otherNames>Boulle, A.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>56c1f59397f0c5.84973513</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD06A9D0-AD15-474D-B621-53A32CE8F822</gtr:id><gtr:title>Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d935415403bb2b7827a6d35549c0c66"><gtr:id>7d935415403bb2b7827a6d35549c0c66</gtr:id><gtr:otherNames>Boulle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>5463bc97058819.78757685</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8213ABE-7E16-44B6-842B-DD87FACE0C06</gtr:id><gtr:title>Mortality after Starting ART in Treatment-na&amp;iuml;ve Adults in 3 Continents: Collaborative Analysis of International Epidemiologic Databases to Evaluate AIDS in Southern Africa and ART Cohort Collaboration Cohorts</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a97bb6f5984e9076ea21c5cccae13d3a"><gtr:id>a97bb6f5984e9076ea21c5cccae13d3a</gtr:id><gtr:otherNames>Boulle, A.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>56c1fbb4973687.69342759</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>982D4755-574A-480C-82EE-EA06D542BCAA</gtr:id><gtr:title>A novel strategy to reduce very late HIV diagnosis in high-prevalence areas in South-West England: serious incident audit.</gtr:title><gtr:parentPublicationTitle>Journal of public health (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/855adc19db6f3ea441e737dc5d91c69b"><gtr:id>855adc19db6f3ea441e737dc5d91c69b</gtr:id><gtr:otherNames>Womack J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1741-3842</gtr:issn><gtr:outcomeId>585d381cb3a1f0.55653190</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C842150F-B075-4E3B-ACFF-921C01410EA7</gtr:id><gtr:title>Mortality of Treated HIV-1 Positive Individuals According to Viral Subtype in Europe and Canada: Antiretroviral Therapy Cohort Collaboration (ART-CC)</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/daf40f9d812f3b78a8fa25bea666f0f6"><gtr:id>daf40f9d812f3b78a8fa25bea666f0f6</gtr:id><gtr:otherNames>May, M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>56c1fc29dc01a8.09993380</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C4DC681-A53D-4EEB-80E0-7FFD3B53D01A</gtr:id><gtr:title>Cumulative incidence of and risk factors for changes to first ART regimen and death prior to a change: the Antiretroviral Therapy Cohort Collaboration (ART-CC)</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d1efdda13511cb84b95a40a6f093861"><gtr:id>8d1efdda13511cb84b95a40a6f093861</gtr:id><gtr:otherNames>Abgrall, S.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>56c1fc9abdf7d9.41960525</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J002380/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>E4AF608A-CDB6-4CE6-AA10-95B3E043E22F</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>8.1  Organisation and delivery of services</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>